The global metabolomics market is anticipated to grow significantly over the forecast period. The study of chemical processes involving metabolites is called metabolomics. The field of metabolomics study the chemical fingerprints left behind by biological (cellular) processes. Some of the important healthcare applications of metabolomics include lead compound discovery, lead compound optimization, biomarker identification, and providing clarity on the mechanism of action, efficacy, and metabolism of a drug.
The emergence of biomarkers as a groundbreaking diagnostic and drug discovery tool will propel the growth of the global metabolomics market. Moreover, the rising adoption rate of metabolomics as a research and development tool will drive the market. Market players pertaining to the fields of biotechnology and pharmaceuticals are increasingly using metabolomics as a drug discovery tool. The use of the concepts of metabolomics proves to be cost-effective especially while conducting toxicological studies on investigational drugs.
Growing global base of geriatric population triggering the incidence rates of target diseases especially diabetes and the rising prevalence of cancer are some of the other drivers of this market. Constantly widening base of target patient population coupled with rising patient awareness levels will drive the growth of this market.
North America is expected to dominate the overall metabolomics market (in terms of market share) throughout the forecast period. The presence of high product commercialization rates coupled with the presence of sophisticated healthcare supporting research and development initiatives are some of the factors attributing to its large market share. Europe follows North America in terms of market share.
The Asia-Pacific metabolomics market on the other hand will outgrow both these regions in terms of growth rate (CAGR). Rising demand for improved pharmaceutical products generated from emerging economies such as India and China is one of the most significant growth contributors to this market.
This research study encompasses a competitive landscape of the metabolomics market. Revenue analysis, product benchmarking, and strategic developments of key market players such as Phenomenome Discoveries Inc., Metabolon, Agilent Technologies, Bruker Corporation, Human Metabolome Technology, and others are also provided in this report.
This report, by Grand View Research, takes a closer look at the metabolomics industry, providing a holistic perspective on market dynamics, trends, supply, and demand. The report deep-dives into the market and segments it on multiple levels and providing key insights on a macro as well as micro-level. The study aims at providing granular information, regarding estimates and forecasts for key product segments including biomarker discovery, metabolite profiling, and metabolite detection. This report also includes market estimates and future forecasts of major application segments namely drug discovery, diagnosis, and toxicology assessment. The report also provides the same level of information for key regional markets.
This research report analyzes various factors which have been driving and inhibiting the global metabolomics market in the past. In addition, the report analyzes the impact of each driver and restraint on the market growth, which forms the base for the market forecast. The report also showcases the opportunities available in the market which may act as future drivers for the market.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.